Commercial agreement for AstraZeneca and Recordati

0

The agreement will cover the commercial rights to  metoprolol tartrate and metoprolol succinate respectively and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe. Recordati will pay AstraZeneca $300 million upon completion of the agreement. AstraZeneca will manufacture and supply the medicines under a supply agreement. The drug product is a beta-blocker indicated for the control of a range of conditions including hypertension, angina pectoris, disturbances of cardiac rhythm, maintenance treatment after myocardial infarction and functional heart disorders with palpitations.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here